Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Long-Term Safety and Tolerability of NOV03 (Perfluorohexyloctane) in Subjects Who Completed Trial NVU-003 (Kalahari Study)

ClinicalTrials.gov ID: NCT04140227

Public ClinicalTrials.gov record NCT04140227. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 29, 2026, 9:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Multi-Center, Open-Label, Single-Arm Extension Clinical Trial to Assess the Extended Long-Term Safety and Tolerability of NOV03 (Perfluorohexyloctane) in Subjects Who Completed Trial NVU-003 (Kalahari Study)

Study identification

NCT ID
NCT04140227
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Bausch & Lomb Incorporated
Industry
Enrollment
256 participants

Conditions and interventions

Interventions

  • NOV03 Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 23, 2020
Primary completion
Jan 4, 2022
Completion
Jan 4, 2022
Last update posted
Mar 3, 2024

2020 – 2022

United States locations

U.S. sites
28
U.S. states
15
U.S. cities
27
Facility City State ZIP Site status
Bausch Site 124 Birmingham Alabama 35233
Bausch Site 125 Scottsdale Arizona 85254
Bausch Site 110 Glendale California 91204
Bausch Site 121 Long Beach California 90805
Bausch Site 102 Mission Hills California 91345
Bausch Site 101 Newport Beach California 92663
Bausch Site 116 Rancho Cordova California 95670
Bausch Site 103 Torrance California 90505
Bausch Site 123 Torrance California 90505
Bausch Site 127 Danbury Connecticut 06810
Bausch Site 129 Fort Myers Florida 33901
Bausch Site 115 Jacksonville Florida 32256
Bausch Site 106 Largo Florida 33773
Bausch Site 117 Tampa Florida 33603
Bausch Site 108 Lake Villa Illinois 60046
Bausch Site 112 Indianapolis Indiana 46260
Bausch Site 119 Edgewood Kentucky 41017
Bausch Site 126 Winchester Massachusetts 01890
Bausch Site 113 Kansas City Missouri 64111
Bausch Site 111 St Louis Missouri 63131
Bausch Site 128 Slingerlands New York 12159
Bausch Site 114 Raleigh North Carolina 27603
Bausch Site 122 Cranberry Township Pennsylvania 16066
Bausch Site 107 Memphis Tennessee 38119
Bausch Site 109 Nashville Tennessee 37205
Bausch Site 120 El Paso Texas 79902
Bausch Site 104 Lakeway Texas 78738
Bausch Site 118 San Antonio Texas 78229

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04140227, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 3, 2024 · Synced Apr 29, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04140227 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →